Abstracts tagged "hyaluronate"

Abstract Number: 2198 • 2019 ACR/ARP Annual Meeting
Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis
Kevin Ong¹, Maria Runa ¹, Wilson Ngai ², Zhimin Xiao ³, Edmund Lau ⁴ and Roy Altman ⁵, ¹Exponent, Inc., Philadelphia, ²Sanofi, U.S. Medical Affairs, Bridgewater, ³Sanofi US, Cambridge, ⁴Exponent, Inc., Menlo Park, ⁵University of California, Los Angeles
Background/Purpose: Some concerns have been raised about subsequent severe acute localized reactions (SALR) (flares, pseudoseptic reactions, etc.) following hyaluronic acid (HA) injections for pain relief…
Abstract Number: 400 • 2018 ACR/ARHP Annual Meeting
Predictors of Response to a Single Intra-Articular Injection of Mannitol-Modified Cross-Linked Hyaluronic Acid (HANOX-M-XL) in Patients with First Metatarsophalangeal Joint Osteoarthritis (hallux rigidus)
Thierry Conrozier¹, Aline Charpentier², Marie Bossert³, Sylvie Mellac-Ducamp⁴ and Laurent Galois⁵, ¹Department of Rheumatology,, Nord Franche-Comté Hospital, Belfort, France, ²Rheumatology, Nord Franche-Comté Hospital, Belfort, France, ³Rheumatology, Nord Franche Comté Hospital, Belfort, France, ⁴Rheumatology, Nevers General Hospital, Nevers, France, ⁵Orthopaedic and trauma surgery, University Hospital of Nancy, Nancy, France
Background/Purpose: To investigate the potential predictors of response to a single intra-articular injection of mannitol-modified cross-linked hyaluronic acid (HANOX-M-XL) in patients with first metatarsophalangeal joint…
Abstract Number: 441 • 2018 ACR/ARHP Annual Meeting
The Presence of Neuropathic Pain Does Not Influence the Response to Hyaluronic Acid (HA) in Patients with Knee Osteoarthritis but HA Injections Modify Pain Phenotype
Evariste Tiendrebeogo¹, Thierry Conrozier², Xavier Chevalier³ and Florent Eymard⁴, ¹Rheumatology, APHP Henri Mondor Hospital, Creteil, France, ²Department of Rheumatology,, Nord Franche-Comté Hospital, Belfort, France, ³Rheumatology, APHP Henri Mondor Hospital, Créteil, France, ⁴Department of Rheumatology, APHP Henri Mondor Hospital, Creteil, France
Background/Purpose: Twenty to forty percent of patients with symptomatic knee osteoarthritis (OA) described neuropathic pain (NP). Several studies have shown that hyaluronic acid (HA) is…
Abstract Number: 2004 • 2018 ACR/ARHP Annual Meeting
Effective Inhibition of Metalloproteases By a Viscosupplement Based on a Hyaluronic Acid Amide (HYADD®4)
Cynthia Secchieri¹, Devis Galesso¹, Cristian Guarise¹, Mauro Pavan¹, Stefano Moro² and Veronica Salmaso², ¹Fidia Farmaceutici, Abano Terme, Italy, ²Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
Background/Purpose: Osteoarthritis (OA) is a disease which results in the degeneration of articular cartilage. The progression of OA involves inflammation in the early stage of…
Abstract Number: 290 • 2016 ACR/ARHP Annual Meeting
Viscosupplemenation Efficacy in Knee Oa Is Similar in Single-Injection Vs. Multi-Week Formulations and Across OA Severity and BMI Subgroups, but Better in Younger Patients
Thayer Mukherjee¹, Fernando Bomfim², Evan Wilder¹, Lauren Browne², Shira Aharon³, Kayleigh Toth¹, Eric Strauss⁴ and Jonathan Samuels⁵, ¹NYU Langone Medical Center, New York, NY, ²Rheumatology, NYU Langone Medical Center, New York, NY, ³NYU Langone Medical Center, Rheumatology, New York, NY, ⁴Orthopedic Surgery, NYU Langone Medical Center, New York, NY, ⁵Division of Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: Hyaluronic acid (HA) viscosupplementation is widely used in patients with knee osteoarthritis (KOA), but variable reported outcomes have impacted its incorporation into treatment algorithms.…
Abstract Number: 1268 • 2015 ACR/ARHP Annual Meeting
Utilization of Viscosupplementation: 2011 – 2013
Gurjit S. Kaeley¹, Myint Thway¹ and Sunita Dodani², ¹Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ²Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Viscosupplementation (VS) is approved in the USA as an option for knee osteoarthritis (OA) pain. Recent American Academy of Orthopedic Surgeons (AAOS) guidelines have…
Abstract Number: 1113 • 2014 ACR/ARHP Annual Meeting
Mayor Trocanter Painful Syndrome. Treatment with Hyaluronic Acid Versus Triamcinolone Acetonide Injections. a Comparative Study
Asuncion Acosta Sr.¹, Arturo Rodriguez de la Serna², Berta Magallares² and Gary Sterba Sr.³, ¹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³rheumatology, rheumatologist, miami, FL
Background/Purpose: Painful syndrome of the mayor trochanter(MTPS).The treatment includes intra-bursal injections with corticosteroids.Steroids.Estimate the efficacy of the treatment with hyaluronic acid injections in comparison to…
Abstract Number: 2139 • 2013 ACR/ARHP Annual Meeting
Do Hyaluronic Acid Injections Delay Total Knee Replacement Surgery?
Thomas Abbott¹, Roy D. Altman², Robert Dimeff³, Michael Fredericson⁴, Vijay Vad⁵, Peter Vitanzo Jr.⁶, Sashi Yadalam¹, Ronald Levine¹, Brad Bisson⁷ and Samir Bhattacharyya⁷, ¹Johnson & Johnson, New Brunswick, NJ, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Stanford University School of Medicine, Menlo Park, CA, ⁵Weill Cornell Medical College, NY, NY, ⁶Rothman Institute, Philadelphia, PA, ⁷DePuy Synthes Mitek Sports Medicine, Raynham, MA
Background/Purpose: More than 27 million adults in the US have knee osteoarthritis (OA), a painful and life-altering disease. Various non-pharmacologic and pharmacologic agents are recommended…
Abstract Number: 2140 • 2013 ACR/ARHP Annual Meeting
Effects Of Intra-Articular Hyaluronic Acid Injections On Gait Pattern In Patients With Knee Osteoarthritis
Bilal Uysal¹, Aysegul Ketenci², Sina Esmaeilzadeh² and Dilsad Sindel², ¹Physical Medicine And Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The aim of this study was to determine the effects of intra-articular hyaluronic acid (HA) injections on gait pattern of both injected and un-injected…
Abstract Number: 893 • 2012 ACR/ARHP Annual Meeting
Nuclear Factor-κB Activation by Type II Collagen Peptide in Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan Via CD44
Tadashi Yasuda, Dept of Sports Medicine, Tenri University, Tenri, Japan
Background/Purpose: Some proteolytic products of cartilage matrix may contribute to cartilage destruction through their catabolic activities. Recently, we have found that a 24-mer synthetic peptide…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].